IP Library Granted Patent US 12,214,191
Granted Patent B2
US 12,214,191 · App. 18/363,442 · Granted Feb 4, 2025

Compositions and methods of applying alternating electric fields to pluripotent stem cells

Inventor: Tali Voloshin-Sela (Haifa, IL)
Assignee: NOVOCURE GmbH
A61N1/36A61N1/36002A61N1/0476
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,214,191
App. No.
18/363,442
Granted
Feb 4, 2025
Kind
B2
Abstract

Disclosed are methods and compositions for preventing or disrupting mitosis of pluripotent stem cells, killing pluripotent stem cells, preventing or disrupting division of pluripotent stem cells, reducing the viability of pluripotent stem cells, slowing the progression or differentiation of pluripotent stem cells, and treating an ectopic pregnancy.

Claims (15)

1. A method of treating ectopic pregnancy comprising:

distributing an alternating electric field to a target site of a subject for a period of time, the alternating electric field having a frequency and field strength, wherein the frequency is 25 kHz to 1 MHz, wherein the field strength is 0.1 V to 10 V/cm,

wherein the target site comprises an ectopic pregnancy.

2. The method of claim 1 , wherein the target site comprises pluripotent stem cells.

3. The method of claim 2 , wherein the pluripotent stem cells are fetal stem cells, embryonic stem cells or induce pluripotent stem cells.

4. The method of claim 1 , wherein the target site is in a fallopian tube or on a cesarean scar of the subject.

5. The method of claim 1 , further comprising administering gefitinib, methotrexate, or a combination thereof to the subject.

6. The method of claim 1 , wherein the subject has elevated levels of human chorionic gonadotropin (HCG).

7. The method of claim 1 , wherein the subject has been identified to have an abnormal pattern in the rise of levels of human chorionic gonadotropin (HCG).

8. The method of claim 1 , wherein the subject has been diagnosed with an ectopic pregnancy.

9. The method of claim 8 , wherein the subject has been diagnosed via ultrasound.

10. The method of claim 1 , wherein the alternating electric field is a tumor-treating field.

11. The method of claim 1 , wherein one or more arrays of electrodes is present on the skin of the subject, wherein the one or more arrays distributes the alternating electric field.

12. The method of claim 2 , wherein the method does not use heat to kill or ablate the pluripotent stem cells at the target site.

13. The method of claim 1 , wherein the alternating electric field prevents or disrupts mitosis of the pluripotent stem cells at the target site.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: VOLOSHIN-SELA, TALI
To: NOVOCURE GMBH
Reel/Frame 066327/0014 →